Overview

A Study to Compare Insulin Pump With Conventional Treatment in Type 2 Diabetes

Status:
Unknown status
Trial end date:
2015-03-01
Target enrollment:
0
Participant gender:
All
Summary
Insulin deficiency resulted from progressive beta cell failure and insulin resistance in type 2 diabetes requires exogenous insulin therapy, escaping from oral antihyperglycemic agents. Previous data have been suggested that continuous subcutaneous insulin infusion (CSII) does not only have efficacy in glucose control but also restore beta cell failure. The investigators plan to compare the efficacy/safety and beta cell function between insulin pump treatment and the intensification of conventional treatment in patients with uncontrolled type 2 diabetes.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Konkuk University Medical Center
Treatments:
Insulin
Insulin, Globin Zinc
Criteria
Inclusion Criteria:

- Type 2 diabetes

- age: 18 ~ 85 yrs

- HbA1c: > 7.5%

- no change of anti-diabetic medication within 3 months

Exclusion Criteria:

- systemic corticosteroid administered within previous 6 months

- pregnancy

- severe liver or renal disease, heart failure

- History of cancer within 5 years

- Thyroid disease

- Anti-obesity drugs or slimming products within previous 3 months